Gefitinib is an orally administered epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used to treat non–small-cell lung cancer (NSCLC).1 The expression of EGFR is strong in epidermis and epidermal appendages, as well as in tumor cells, and so treatment with gefitinib can result in dermatologic adverse effects with various manifestations.1 We report a case of necrolytic migratory erythema (NME)-like skin lesions developing during treatment with gefitinib. We believe that this case demonstrates a rare cutaneous adverse reaction to gefitinib and highlights the need for suspicion of this rare condition during the course of treatment with gefitinib.
Seong JY, Kong SH, Choi YS, Suh HS. Necrolytic Migratory Erythema–like Skin Lesion During Gefitinib TreatmentA Rare Cutaneous Adverse Reaction. JAMA Dermatol. 2016;152(8):947-948. doi:10.1001/jamadermatol.2016.1098